Stocks Will Be in Focus: Aurobindo Pharma, Cipla, HDFC Bank

: The US FDA inspected Unit-VI, an API manufacturing facility of the company’s subsidiary Apitoria Pharma, at Anakapalli, Andhra Pradesh, from August 24 to 28, 2026. The inspection concluded with three observations, which are procedural in nature. Cipla: The US FDA has classified the inspection of Unit 3, a manufacturing facility of Cipla’s subsidiary InvaGen Pharmaceuticals Inc. in the US, as Voluntary Action Indicated (VAI). The inspection was conducted from July 13 to 17, 2026. HDFC Bank: Sashidhar Jagdishan has decided not to seek reappointment as Managing Director & CEO of HDFC Bank. He will retire from the bank’s services effective October 26, 2026. The Board has decided to fast-track the selection and appointment of his successor well in advance. Results Today: Investors will track quarterly earnings from LEAP India, Milky Mist Dairy Food, Setco Automotive, Cressanda Railway Solutions, Dachepalli Publishers, and Standard Surfactants today. Disclaimer: Investments in securities are subject to market risk. This is for educational purposes only. Investors must verify information before investing and consider their financial position & risk profile.